Encoded Therapeutics Achieves FDA Alignment on ETX101 Pivotal Study Design for Dravet Syndrome

For CGT manufacturers tracking IND-to-BLA transitions, Encoded Therapeutics' completed RMAT designation meeting with FDA signals a defined regulatory runway for ETX101, its AAV9-mediated gene regulation therapy targeting SCN1A-positive Dravet syndrome. The alignment, reached following an Initial Comprehensive Multidisciplinary RMAT meeting, establishes the framework under which the company will pursue pivotal-stage development.

The agreed pivotal design is the 30-patient ENDEAVOR Part 2 trial, now initiated. It evaluates a single intracerebroventricular administration of ETX101 versus sham control over 52 weeks in children aged 6 months to under 4 years. Primary endpoint is monthly seizure frequency reduction; Bayley-4 cognitive scores serve as the key secondary endpoint. A separate open-label expansion cohort, Part 1B, will assess safety and preliminary efficacy in patients aged 4 to under 18 years.

Interim data from the broader POLARIS clinical program, presented at the 2026 American Society of Gene and Cell Therapy Annual Meeting, covered 21 treated participants across the ENDEAVOR, WAYFINDER, and EXPEDITION studies. Findings indicated substantial seizure reductions and early neurodevelopmental improvements, providing the clinical signal supporting advancement into the pivotal stage.

ETX101 was engineered around a specific technical constraint: the SCN1A coding sequence is too large for conventional AAV packaging. The therapy instead uses an engineered transcription factor approach to selectively upregulate endogenous SCN1A expression in GABAergic inhibitory interneurons, a mechanism validated in preclinical work published in Human Gene Therapy. That cell-type specificity has direct implications for GMP process development, particularly around vector characterization, potency assay design, and lot release criteria under 21 CFR Part 211 and applicable biologics GMP frameworks.

For QA and manufacturing leads, the RMAT pathway carries practical weight: it enables more frequent FDA interaction during development and can accelerate rolling BLA review, but it also compresses the timeline in which GMP scale-up, process validation, and comparability studies must be completed. Enrollment completion for ENDEAVOR Part 2 is expected by end of 2026, with initial data readouts projected for 2027, leaving a narrow window to align commercial-scale manufacturing with pivotal study supply requirements.

The 2027 data readout will serve as the first measurable checkpoint against which ETX101's regulatory and manufacturing timelines can be assessed in parallel.

Source: CGTLive via cgtlive.com, May 22, 2026. Interim POLARIS data presented at the 2026 ASGCT Annual Meeting; FDA pivotal study alignment announced March 25, 2026.